iCAS-LV
Overview
The intelligent Computer Assessment Support (iCAS-LV™) is a computer-based Quantitative Changes Analysis of Lesion Volumetric Changes for radiological follow-up of longitudinal liver contrast-enhanced CT (ceCT) volumetric scans. HighRAD’s AI imaging platform is designed to track the entire patient journey, offering profound insights into disease progression through advanced quantitative, multi-organ analysis. It provides quantitative imaging analysis, automated lesion measurement, workflow integration, and standardized reporting, enabling radiologists, oncologists, and pharmaceutical research teams to gain deeper disease insight, make more confident clinical decisions, and improve treatment planning. The technology enhances disease understanding and significantly improves treatment outcomes, boosting radiologist productivity, and enabling quicker, more confident diagnoses.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-generated lesion detection for up to 3x faster oncology reporting
- Accurate volumetric measurement of known and unknown lesions
- Longitudinal comparison of findings (through all available studies)
- Automated report generation for streamlined RECIST 1.1 documentation
- Multi-organ view for complete standardized reporting
- Seamless connectivity, integrating with all CT, MRI, and PET systems
- AI-Powered Longitudinal Quantitative Analysis using Simultaneous Deep Learning technology (SimU-Net)
- Automatic Lesion Detection & Segmentation
- Data Processing and Integration
Use Cases
- Tracking oncology patient journey
- Radiological follow-up of longitudinal liver contrast-enhanced CT (ceCT) volumetric scans
- Evaluating disease progression and treatment efficacy
- Streamlining data retrieval and analysis for faster reporting
- Supporting personalized treatment planning
- Pharmaceutical tool for evaluating treatment or drug responses and tracking clinical studies
What Physicians Need to Know
iCAS-LV is a powerful assistive tool for liver lesion evaluation, particularly beneficial for longitudinal comparisons and standardized RECIST 1.1 reporting. Remember it's intended to support, not replace, physician judgment for diagnosis and patient management decisions. Leverage its automated volumetric analysis and registration features to enhance efficiency and consistency in your workflow.
The system is designed for seamless integration into existing radiology workflows by receiving multi-phase volume datasets from PACS devices and returning processed output in DICOM format. This ensures compatibility and efficient data exchange within a standard imaging infrastructure.
Details
| Category | Oncology AI |
| Pricing | Contact for pricing |
| Deployment | PC-based, self-contained software application that integrates with PACS devices. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated The iCAS-LV received FDA 510(k) clearance (K231690) on March 1, 2024. It is a PC-based, self-contained, noninvasive image analysis software application intended to receive multi-phase volume datasets from PACS devices, process them, and transfer the output in DICOM format. It provides tools for visualization, measurements, segmentation, annotation, image registration, processing, and reporting, supporting physicians in evaluating liver lesions. |
| Integrations | |
| EHR | Not specified |
| Specialties | Nuclear Medicine, Oncology, Radiology |
What the Web Says
iCAS-LV by HighRAD is an AI-powered imaging platform designed to revolutionize oncology care by accelerating and improving the accuracy of cancer detection, volumetric measurement, and longitudinal comparison of lesions in liver contrast-enhanced CT scans. It aims to streamline oncology reporting, enhance disease understanding, and ultimately improve treatment outcomes and radiologist productivity.
Overall: PositiveStrengths
- AI-generated lesion detection for up to 3x faster oncology reporting.
- Accurate volumetric measurement of known and unknown lesions.
- Longitudinal comparison of findings across all available studies.
- Automated report generation for streamlined RECIST 1.1 documentation.
- Multi-organ view for complete standardized reporting.
- Enhances disease understanding and improves treatment outcomes.
Limitations
- No specific cons for iCAS-LV were found in the search results.
- General 'ICAS' reviews (not specific to iCAS-LV or HighRAD) on platforms like Indeed and Reddit discuss challenges with management, work-life balance, and the difficulty of associated professional qualifications, but these are not relevant to the iCAS-LV product itself.
Based on reviews from: High-Rad.com, Indeed.com, Reddit, American Heart Association Journals, Capterra, G2
Last updated: 2026-07-18
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate iCAS-LV
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for iCAS-LV.
ICAS-DC vs RSHS | Elimination Round IABL Inaugural Season | 4/11/26
